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The term New Medicine describes our new age of health-care 
reform and biotechnological discoveries. While offering hope 
for a healthier and more productive nation, New Medicine 
challenges us to come to terms with the cost, the complex 
social issues resulting from medical breakthroughs, and the 
limits to autonomy. A simplified ABC overview of some of the 
many bioethical dilemmas that now confront us are offered in 
this article. 
A is for Affordability 
America spends nearly 14% of its GDP on health care, about 
twice as much as other industrialized countries. Despite ex-
penditures of nearly $1 trillion, some 37 million Americans are 
without health coverage. Even those who have health insur-
ance are aghast at the high cost of becoming ill. 
Medical expenditures continue to mount because of: 1) our 
aging population, 2) the increasing prevalence of chronic 
diseases, 3) new expensive medical technology, 4) a demand-
ing citizenry, 5) physicians' practice of defensive medicine, 
and 6) no personal incentive to minimize expenses. Managed 
care has been touted as an effective means to contain costs. 
Capitation will replace fee-for-service. Increased reliance on 
gatekeeping primary care providers is expected to curtail the 
overutilization of specialists and expensive testing. Because 
the incentive is to do less, not more, itis expected that managed 
care will reduce costs in the short term. What is of concern, 
however, is whether managed care will reduce the high quality 
of care that Americans expect and demand. 
If we accept that our resources are finite, and medical costs 
will not abate, then we must accept that we cannot afford all the 
health care we desire. In order to assure universal access 
should we resort to rationing? One proposal is to offer a basic 
package to all Americans irrespective of their ability to pay. 
Those who want more will bear the added costs themselves. 
This approach pits the wealthy against the poor, and arguably 
violates the bioethical principle of distributive justice. On the 
other hand, if the basic health-benefit package is carefully 
defined, all patients should enjoy excellent medical care, 
forgoing only treatment that is experimental, unproven, des-
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perate, futile, or prohibitively expensive. 
B is for Breakthroughs 
Medical discoveries are accelerating at a breakneck pace, due 
largely to breakthroughs in cracking the genetic code. We can 
isolate and clone genetic material that directs the production of 
vital body chemicals such as enzymes, hormones, and proteins. 
The National Institutes of Health are well into their multicenter 
Human Genome Project; scientists are expected to complete this 
task by the year 2010. The project maps the entire genetic structure 
and function of human cells, which will unlock secrets of cellular 
physiology and pathology. Treatment for once-incurable condi-
tions will swiftly follow by replacing the missing or defective 
genes. 
Gene drugs have apparently cured two young girls with severe 
combined immunodeficiency and are being used in experimental 
trials to treat such disparate diseases as cancer, hemophilia, 
hypercholesterolemia, and cystic fibrosis. In the near future, they 
will be standard fare in the fight against many other diseases 
including diabetes and hypertension. A brave new world of 
medical triumphs will mark the turn of the millennium. But these 
breakthrough technologies are likely to be expensive, threatening 
to stretch and strain our finite health care budget. And genetic 
engineering is likely to create new ethical dangers. 
Understanding the genetic code allows us to control not only 
diseases, but also such things as eye color, height, and intelli-
gence, since these attributes, like all cellular functions and prod-
ucts, are under direct genetic DNA control. Bioethicists are rightly 
nervous and suspicious about this new power to tinker with nature. 
Take height as an example. We would surely welcome a genetic 
cure for a child stunted by growth hormone deficiency. Currently 
these children are treated with injections of human growth hor-
mone, with only partial success. It is quite another matter, how-
ever, to select out tall progenies by genetic manipulation of 
otherwise perfectly normal individuals. Tallness is socially ad-
vantageous. Sports value it, the sexes crave it, and businesses 
reward it (six-foot graduates command a starting salary 12.4% 
more than their shorter classmates). Height even wins presiden-
cies; the taller candidate was victorious in 80% of all presidential 
elections in this century. Once the height gene is cloned and 
clinically available, should parents be allowed to opt for taller 
offspring? 
The new genetics will also identify aberrant gene markers that 
can predict a disease state long before it becomes clinically 
manifest. Such knowledge is likely to invite discriminatory prac-
tices in insurance underwriting and in employment. Genetic 
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testing additionally raises ethical and legal issues of consent and 
privacy. 
Breaking the genetic code breaks the taboo against eugenics, 
that notorious science of improving the hereditary qualities of 
the human race. Prudence and history remind us that selfish 
tampering with nature frequently leads to unintended and unde-
sirable outcomes. What moral code do we adopt to constrain the 
new genetics? Are we apt to repeat those Nazi experiments in 
eugenics to produce a superior race? Ethical guidelines lag far 
behind scientific strides, yet the genetic genie is virtually out of 
the bottle. Will the glare of its potential for good blind us to the 
evil it can unleash? 
Another technological breakthrough of the New Medicine is 
the marvelous electronic communication systems that instantly 
record, collect, store, and transmit information. Medical charts 
will become obsolete. Poor communication, illegible record 
keeping, and misplaced prescriptions will thankfully disappear. 
Patient records will be instantly retrievable, as will the latest in 
medical research. Patient care will be dramatically more effi-
cient. 
But we risk losing the privacy and confidentiality of our 
medical lives by getting on this electronic information super-
highway. The health care system is no longer just doctors, nurses 
and patients.lt is now populated by assorted faceless health plan 
administrators, third-party payers, governmental agents, and 
purveyors of medical products. Protecting the confidentiality of 
these electronic records will require much care, foresight and 
sensitivity. Irrespective of the safeguards employed, one thing is 
clear: In the New Medicine, like it or not, many more in the 
system will know and share our medical profiles. 
One other concern. Medical informatics threatens the 
doctor-patient relationship with its offer to take histories by 
computer, and physical examination and surgery by programmed 
robots. Meaningful personal contact with a health care provider, 
who may not even be a doctor, is likely to be brief. Advocates of 
computer medicine believe in its superiority, because the meth-
odology employs outcomes-determined algorithms with proven 
cost-effectiveness. Others wisely ask whether high tech can ever 
supplant the high touch of the doctor's hand, her placebos, and 
her humanity. 
C is for Choice 
which neither cures nor palliates. Examples of medical futility 
include treating patients in a persistently vegetative state, or 
condemning a patient to an irreversible permanent dependence 
on intrusive life support in an intensive care unit. Families are 
sometimes known to demand such non-beneficial treatment. 
Unfortunately, recent case-law appears to favor such family 
requests for continued expensive futile treatment. Should this 
trend continue, autonomy's triumph over paternalism will waste-
fully bloat our health care budget deficit. 
A final ethical dilemma: Euthanasia. Supporters of euthanasia 
assert that the right to die is the logical and ultimate expression 
of self-determination. Opponents, on the other hand, question 
the existence of such an absolute right, pointing to the sanctity 
of life and the dangers of abuse should mercy-killing be legal-
ized. 
Such abuse concerns led to the narrow 54 to 46 rejection of 
aid-in-dying initiatives in Washington and California in 1992 
and 1993. However, this past November 8, voters in Oregon 
approved Measure 16, which sanctions any terminally ill patient's 
request for drugs to ~nd life. Around the same time, the Michi-
gan court absolved Dr Kevorkian of wrongdoing. Kevorkian is 
the pathologist who assisted in the suicidal death of21 patients. 
It is easy to predict that legalizing euthanasia will rank as the 
premier ethical issue as we enter the era of the New Medicine. 
Conclusions 
The modern doctor faces a bewildering array of ethical dilem-
mas in the practice of her profession. The selection seems 
endless. In addition to those discussed earlier, we have test-tube 
babies and surrogate motherhood, life support for very low 
birth-weight infants and organ transplantation, to name just a 
few. Observers of America's health scene lament that physi-
cians are not very good at identifying or solving bioethical 
issues. Pertinently, one might ask whether and how our medical 
schools and teaching hospitals are preparing future generations 
of doctors to meet ethical challenges-those recognized and 
those yet undefined. Never before in the history of medicine has 
its art been more dangerously asynchronous with, and outpaced 
by, its science. 
Patient autonomy is a bioethical principle 
of recent vintage, an outgrowth of Ameri-
can laws governing privacy and liberty 
rights. Autonomy underpins many widely 
accepted western medical practices such as 
informed consent, living wills, and do-not-
resuscitate orders. It properly empowers 
the patient with the control of her body, 
even for decisions that run counter to the 
doctor's advice. But patient choice, like 
free speech, has its limits. Testing these 
limits of autonomy is at the heart of the 
current heated debate on two bioethical 
issues: Futile treatment and euthanasia. 
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